EGFR PCR
A focused test that looks for specific changes in the EGFR gene.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Purpose of the test
- Detect common EGFR mutations.
- Become a screening examination before a wider panel.
Informs decisions
- Categories of EGFR-targeted therapies that are worthy of discussion.
How the test is done
The genetic material from the tumor sample is amplified and read at certain points.
- Sample type
- Block tumor tissue or blood
- Estimated result time
- Generally a few days to two weeks.
Limitations
- Only checks specific points, not the entire gene.
- Certain groups of mutations such as exon 20 insertions require other methods.
- Negative results should be interpreted in light of the broader panel.
Related
Cancer types
Markers tested
Not displayed
TanyaKanker does not display test-cost estimates. Ask the laboratory or facility providing the test for cost details directly.
Sources
- NCI Dictionary of Cancer Terms(lembaga)
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
To check
- Lung Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- EGFR
Biomarker
Reason: Diperiksa melalui
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.